Streetbeat News

Products Services

OPTT

Ocean Power Technologies (OPTT) has received a $1.6 million order for multiple WAM-V 16s from Sulmara. This could potentially boost the company's revenues and profitability.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:16 pm

LCTX

Lineage Cell Therapeutics, Inc. (LCTX) announced that its CEO, Brian M. Culley, will present at the 'Mapping the Future of Geographic Atrophy' session at Eyecelerator 2023. The session will also feature executives from Apellis Pharmaceuticals, Iveric Bio, Annexon Biosciences, Aviceda Therapeutics, and ONL Therapeutics. Additionally, results from a Phase 1/2a clinical study of RG6501 (OpRegen) will be presented, showing evidence of rapid improvement in outer retinal structure and continued clinical benefit. RG6501 is being developed under a collaboration between Lineage, Roche, and Genentech.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:16 pm

FHTX

Foghorn Therapeutics Inc. (NASDAQ:FHTX) will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting. The company will present data from its selective EP300 and CBP degrader programs, and preliminary results from a Phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:14 pm

WKSP

Worksport Ltd. (NASDAQ: WKSP) has announced that its subsidiary, Terravis Energy, has increased R&D for its Cold Climate Residential Heat Pump, anticipating large-scale growth in the North American and global markets. The North American market for heat pumps is estimated at $7.3 billion, with a projected 9% annual growth rate between 2023 and 2032, reaching $24 billion by 2028. Globally, the residential heat pump market is expected to reach $121.5 billion by 2032. Worksport CEO Steven Rossi stated that the Terravis heat pump is a significant product for Worksport as it plans to introduce more energy-based products.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:12 pm

BFLY

Butterfly Network (BFLY) and Forest Neurotech have announced a five-year co-development agreement to develop the first implanted, whole-brain neural interface using Butterfly's Ultrasound-on-Chip technology. The deal includes $20MM in milestones paid to Butterfly with additional revenue anticipated upon commercialization for every unit sold. This collaboration is part of Butterfly's initiative to encourage innovation and expedite the potential of its disruptive chip technology through new applications and in adjacent markets.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:11 pm

MOTS

Motus GI has received FDA clearance to commercialize its Pure-Vu EVS Gastro and Gen 4 Colon products. This approval could potentially boost the company's market presence and revenue.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:11 pm

TSHA

Taysha Gene Therapies has presented new preclinical in-vitro data on TSHA-102 in Rett Syndrome at the European Society of Gene & Cell Therapy 30th Annual Congress. The data showed that the miRARE control element downregulates MECP2 transgene and protein expression in response to cellular levels of MeCP2 in cell culture models. Clinical data from two adult patients dosed with TSHA-102 will be reported in mid-November, and the first pediatric Rett syndrome patient is expected to be dosed in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:10 pm

AMSC

AMSC, a provider of megawatt-scale power resiliency solutions, has announced $37 million of new energy power systems orders. The orders include various power system components and are expected to be recognized in fiscal year 2024. The orders were driven by robust demand in the markets AMSC serves, with half of the orders coming from industrials and a quarter from renewables. The remaining orders came from other projects, including utility and military projects.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:10 pm

NKGN

NKGen Biotech has received FDA clearance for its Investigational New Drug application for SNK01 NK cell therapy to treat Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:10 pm

ITRM

Iterum Therapeutics has completed enrollment in its REASSURE Phase 3 clinical trial of oral Sulopenem for uncomplicated urinary tract infections.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:09 pm